Business context and reporting period
Indivior Pharmaceuticals, Inc. filed this Form 8-K on October 6, 2026, to supplement the joint proxy statement/prospectus for its proposed merger with Supernus Pharmaceuticals. This is a merger-disclosure update, not a periodic financial-results report.
Under the August 1, 2026 merger agreement, Indivior’s subsidiary will merge into Supernus, with Supernus surviving as an Indivior subsidiary. Indivior is to be renamed Supernus, Inc. Indivior and Supernus scheduled special stockholder meetings for October 15, 2026.
Financial information and material changes
The filing does not report period revenue, profit, cash flow, operating margins, or current liquidity. It updates financial-advisor valuation analyses in the proxy materials, using management-provided estimates approved for Cantor Fitzgerald’s use:
- Estimated cash and debt: Supernus: approximately $372 million of cash and no debt. Indivior: approximately $249 million of cash and approximately $500 million of debt.
- Special dividend: The analyses account for a $1 billion Indivior Special Dividend, which would be funded with additional indebtedness.
- Discounted cash flow analyses: Cantor’s indicated reference range was $50.55–$59.50 per Supernus share and $24.20–$43.90 per Indivior share, with Indivior’s range adjusted for the Special Dividend. These are valuation-analysis outputs, not transaction consideration or market-price guidance.
- Key DCF assumptions: Valuation dates were June 30, 2026; discount rates were 9.5%–11.5% for Supernus and 8.0%–10.0% for Indivior. Both analyses used perpetual terminal growth rates from negative 10.0% to positive 3.0% after 2040.
The supplement revises certain share-count inputs and descriptions of cash, debt, dividend adjustments, and valuation methods used in Cantor’s selected-company, DCF, contribution, and precedent-transaction analyses. It does not provide enough information to quantify a change in the merger’s economics versus the prior proxy disclosure.
Litigation, outlook, and risks
Supernus received stockholder demand letters, and two purported stockholder complaints were filed in New York alleging disclosure deficiencies. Supernus says the claims are without merit and denies wrongdoing. Indivior and Supernus nevertheless chose to make supplemental disclosures to reduce litigation burden and the risk of delay, without admitting liability or that further disclosure was legally required.
The filing identifies risks to the proposed merger, including failure to obtain stockholder or regulatory approvals, unmet closing conditions, competing proposals, the fixed exchange ratio, added debt for the Special Dividend, integration challenges, unrealized synergies, transaction costs, litigation, and potential failure to qualify for intended tax treatment. Completion and timing are not assured. The filing gives no new operating or financial guidance.
Important facts for investors to verify
- Read the definitive joint proxy statement/prospectus together with this supplement, especially the merger terms, exchange ratio, Special Dividend financing, and Cantor valuation assumptions.
- Confirm the status and results of both companies’ October 15, 2026 special meetings and any required regulatory approvals.
- Review subsequent filings for updates on the stockholder complaints, merger conditions, expected closing, and costs or liabilities.
- Assess the effect of the planned $1 billion Special Dividend and associated indebtedness on Indivior and the combined company; this filing does not provide a complete post-transaction liquidity or leverage forecast.